Rasmussen encephalitis is a rare, progressive inflammatory brain disease in which one hemisphere of the brain comes under sustained immune attack, leading to worsening seizures, loss of motor and cognitive function on one side of the body, and, in many cases, the eventual need for surgery to disconnect or remove the affected hemisphere. It primarily strikes children, though adults can develop it too, and its cause remains incompletely understood despite decades of research. What makes it especially challenging is that the seizures it produces are almost always resistant to standard anti-seizure medications, pushing treatment decisions into difficult territory early on.
How Rasmussen Encephalitis Unfolds
The disease typically progresses through recognizable stages. It often begins with a prodromal phase where a child experiences occasional seizures that might initially respond to medication. This early window can last several months on average before the disease shifts into an acute stage marked by frequent, hard-to-control seizures that clearly originate from one side of the brain. A hallmark of this acute phase is epilepsia partialis continua, a form of continuous focal jerking, usually in a hand, arm, or one side of the face, that can persist for hours or days. This type of relentless seizure activity occurs in a large majority of patients during the acute stage.1Seizure. Rasmussen encephalitis: From immune pathogenesis to treatment options
Alongside the seizures, patients develop progressive weakness on one side of the body (hemiparesis) and cognitive decline. Language, memory, and attention can all deteriorate, especially when the dominant hemisphere is involved. Eventually the disease enters a residual stage where seizures may become somewhat less frequent, but by that point significant neurological damage has already occurred. The speed of this progression varies: some children move from first seizure to severe disability within a year, while others experience a more gradual decline over several years.
The Immune Attack on the Brain
Rasmussen encephalitis is driven primarily by the body’s own immune system turning against brain tissue in one hemisphere. The main culprits are cytotoxic T cells, a type of white blood cell that normally kills virus-infected cells but in this disease attacks healthy neurons instead. Pathology studies of brain tissue from affected patients consistently show these T cells infiltrating the cortex, parking themselves next to neurons, and releasing cell-killing molecules directly into the nerve cells, triggering neuronal death.2PubMed. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen’s encephalitis This isn’t a passive bystander process. Microscopy has shown these immune cells oriented with their toxic cargo aimed squarely at neurons, and the neurons respond by undergoing programmed cell death.
The T-cell attack doesn’t happen in isolation. Microglia, the brain’s resident immune cells, also become activated and contribute to the inflammatory cascade. Together, the infiltrating T cells and the locally activated microglia create a destructive environment that progressively erodes the cortex of the affected hemisphere.3PubMed Central. Molecular and spatial heterogeneity of microglia in Rasmussen encephalitis Another layer of damage involves astrocytes, the brain’s support cells, which become overly reactive in a process called astrogliosis, further disrupting normal brain function.4PubMed Central. The dynamics of brain T cell populations during the course of rasmussen encephalitis: from expansion to exhaustion
This understanding of T cells and microglia as the primary drivers has shaped treatment thinking. Researchers have proposed that immunomodulatory treatments aimed at these specific immune players, particularly if started early, might slow the disease’s destructive march through the hemisphere.5PubMed Central. Rasmussen’s encephalitis: mechanisms update and potential therapy target
The Antibody Debate and What Triggers the Disease
For years, researchers suspected that antibodies against a brain protein called GluR3, a type of glutamate receptor, were central to the disease. Early animal experiments showed that immunizing rabbits against GluR3 could produce a neurological disorder resembling Rasmussen encephalitis, and the antibodies themselves could kill brain cells in the lab through a complement-mediated process.6PubMed. Glutamate receptor GluR3 antibodies and death of cortical cells Some children improved after plasma exchange to remove these circulating antibodies, which seemed to clinch the case.
The picture turned out to be more complicated. Later studies failed to reliably detect GluR3 antibodies in many patients who clearly had the disease based on clinical and pathological criteria. When researchers tested large numbers of sera from epilepsy patients, the antibodies were found only at low levels in a small minority, and the binding appeared to be nonspecific. None of the tested sera affected the function of the receptor in ways consistent with a disease-causing role.7PubMed. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis To make matters murkier, GluR3 antibodies also showed up in patients with other types of epilepsy that had nothing to do with Rasmussen encephalitis.8JAMA Neurology. Diagnostic and Pathogenic Significance of Glutamate Receptor Autoantibodies
The current consensus is that while autoantibodies may play some contributing role, the T-cell-driven attack is the primary engine of destruction. Antibodies alone can’t explain the disease, and they aren’t reliable diagnostic markers.
What actually triggers this immune assault in the first place remains an open question. One early hypothesis pointed to cytomegalovirus (CMV). A study using in-situ hybridization found CMV genetic material in brain tissue from seven of ten Rasmussen encephalitis patients, compared with only two of forty-six controls with other neurological diseases.9The Lancet. Cytomegalovirus and Rasmussen’s encephalitis The idea was that a viral infection might set off an immune response that then goes haywire, attacking brain tissue even after the virus is cleared. Other researchers have looked at different viruses, but no single infectious agent has been consistently linked to the disease across studies. The viral trigger hypothesis is plausible but unproven.
Genetic Susceptibility
Since Rasmussen encephalitis is so rare and doesn’t run in families in any obvious pattern, the search for genetic risk factors has been slow. Whole-exome sequencing studies have identified variants in genes related to how the immune system presents antigens and responds to viral infections. Genes in the HLA class II family, which helps the immune system distinguish self from non-self, showed multiple variants in Rasmussen encephalitis patients. A gene involved in antiviral defense, TRIM41, also showed up.10PubMed Central. Genetic Factors in Rasmussen’s Encephalitis Characterized by Whole-Exome Sequencing
These findings suggest that certain people may carry immune-system wiring that makes them more vulnerable to the kind of misdirected T-cell response seen in the disease, perhaps in combination with an environmental trigger like a viral infection. But these are still early findings from small cohorts, and no genetic test can predict or diagnose Rasmussen encephalitis.
How the Diagnosis Is Made
Diagnosing Rasmussen encephalitis can be frustratingly slow because the early stages look like many other forms of childhood epilepsy. The combination of features that eventually raises suspicion includes seizures that progressively worsen and resist medication, motor weakness developing on one side, and cognitive decline, all pointing to one hemisphere.
MRI is central to the workup. Early on, imaging may show subtle signal changes in the cortex of one hemisphere. As the disease progresses, the affected hemisphere develops increasingly obvious atrophy, with the cortex visibly shrinking over serial scans. Tracking MRI changes over time has emerged as a useful biomarker for both diagnosing the disease and monitoring its progression. Imaging also helps rule out other conditions that can mimic the presentation, such as cortical dysplasia, tumors, or other forms of encephalitis.11PubMed Central. A case of rasmussen encephalitis: the differential diagnoses and role of diagnostic imaging
Formal diagnostic criteria established by a European consensus group combine clinical features (focal seizures, hemiparesis, cognitive decline), EEG findings (slowing and seizure activity over one hemisphere), MRI abnormalities (unilateral cortical atrophy or signal changes), and, when available, brain biopsy showing T-cell infiltration and microglial activation.12PubMed. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement A biopsy is not always required if the clinical and imaging picture is clear enough, but when the diagnosis is uncertain, tissue examination showing the characteristic inflammatory pattern can confirm it.
Emerging biomarkers may eventually speed up diagnosis. Researchers are investigating blood and cerebrospinal fluid markers such as neurofilament light chain, a protein released when nerve fibers are damaged, and specific cytokine profiles that reflect the underlying inflammation. These could help distinguish Rasmussen encephalitis from other seizure disorders earlier in the course.
Immunotherapy and the Window of Opportunity
Because the disease is immune-mediated, treatments aimed at calming or redirecting the immune system have been tried extensively. Steroids, intravenous immunoglobulins (IVIG), and drugs that suppress T-cell activity like tacrolimus have all shown some benefit in case reports and small series. None of these therapies has been shown to halt the disease outright, and none has been proven superior to the others in head-to-head comparisons.13PubMed Central. An immunotherapy effect analysis in Rasmussen encephalitis
A recurring finding is that immunotherapy appears more effective at slowing functional decline than at controlling the seizures themselves. Even when treatments significantly reduce T-cell counts in brain tissue, intractable seizures often persist, suggesting that once the inflammatory damage reaches a certain threshold, the seizure-generating circuitry becomes somewhat independent of the ongoing immune activity.14PubMed Central. An immunotherapy effect analysis in Rasmussen encephalitis
Timing, then, may be everything. A study examining early initiation of IVIG found that patients who began treatment while seizures were still relatively infrequent, before daily seizures and motor deficits had set in, had markedly better outcomes. Five patients started on IVIG early avoided surgery entirely, and three were seizure-free at last follow-up. Their brain scans also showed relatively preserved gray matter in the affected hemisphere. In contrast, the two patients in the study who eventually needed surgery had already developed severe weakness and daily seizures by the time immunotherapy began.15PubMed. Role of Early Intravenous Immunoglobulins in Halting Clinical and Radiographic Disease Progression in Rasmussen Encephalitis This is a small study and not definitive, but it reinforces the broader clinical impression that the earlier you intervene, the more you can preserve.
Hemispherotomy and Seizure Outcomes
For most patients, surgery eventually becomes the primary treatment consideration. Hemispherotomy, a procedure that disconnects the affected hemisphere from the rest of the brain while leaving most of the tissue in place, is the standard surgical approach. It is a dramatic intervention by any measure, but for a disease that otherwise destroys an entire hemisphere piecemeal, it trades a controlled loss for an uncontrolled one.
Seizure outcomes after hemispherotomy are generally good, though not perfect. One large surgical series found seizure-freedom rates of about 82% at one year, dropping to roughly 64% at five years and 56% at ten years.16PubMed Central. Seizure Outcomes and Reoperation in Surgical Rasmussen Encephalitis Patients Those numbers reflect the reality that some patients experience seizure recurrence over time, sometimes because of incomplete disconnection of the diseased hemisphere. Achieving a complete disconnection on the first operation significantly improved the chances of long-term seizure freedom, and patients who needed a second surgery to complete the disconnection achieved seizure freedom in every case.17PubMed Central. Seizure Outcomes and Reoperation in Surgical Rasmussen Encephalitis Patients
Another study of 44 patients reported that about 68% were seizure-free at last follow-up, with 70% in the two best outcome categories. The mean age at surgery was around 9 years, and the average time from seizure onset to surgery was about two and a half years. Before surgery, the vast majority already had some degree of weakness on one side and reduced cognitive performance.18PubMed. The Important Role of Hemispherotomy for Rasmussen Encephalitis: Clinical and Functional Outcomes
An interesting counterintuitive finding from surgical data is that patients with a shorter duration of hemiparesis before surgery, meaning their motor function hadn’t been impaired for very long, were actually less likely to be seizure-free afterward and more likely to need reoperation.19PubMed Central. Seizure Outcomes and Reoperation in Surgical Rasmussen Encephalitis Patients This probably reflects the fact that earlier surgery catches the disease while it is still actively spreading, making complete disconnection harder and the remaining hemisphere less fully adapted to taking over functions from the diseased side.
Life After Hemispherotomy
Disconnecting half the brain inevitably produces deficits. After hemispherotomy, patients develop permanent weakness on the opposite side of the body (or worsening of weakness that was already present) and lose peripheral vision on that side. Data from a global registry found that hemiparesis increased from about 22% of patients before surgery to 97% afterward. Over a third lost the ability to run unassisted, and a smaller proportion lost the ability to walk, stand, or roll independently. Visual deficits jumped from 16% before surgery to about 84% after.
Despite these motor and visual losses, the picture for overall quality of life is more encouraging. About 86% of caregivers reported improvement in quality of life after surgery, and over half wished it had been done sooner. Only about 13% expressed regret. Seizure freedom, which the surgery achieved in about 85% of cases in this registry, correlated strongly with quality-of-life improvement.
Cognitive recovery after hemispherotomy, particularly when the dominant hemisphere for language is removed, is more nuanced. A long-term follow-up study of patients who underwent left hemispherotomy found that verbal intelligence, declarative memory, and understanding of word meanings normalized within about three years. However, more complex language abilities like grammar, working memory, and attention remained weaker in the long term. Outcomes varied considerably between individuals, with some recovering more functions than others.20PubMed Central. Cognitive outcome after left functional hemispherectomy on dominant hemisphere in patients with Rasmussen encephalitis: beyond the myth of aphasia
The brain’s capacity to reorganize language functions to the remaining hemisphere is one of the more remarkable aspects of recovery. Research tracking cortical changes in the intact right hemisphere after left hemispherotomy has identified structural patterns associated with better language outcomes, including the development of a more integrated language network in the surviving hemisphere.21PubMed. Structural signatures of language reorganization after left hemispherotomy in patients with Rasmussen’s encephalitis This kind of plasticity is more robust in younger children, which is one reason the timing of surgery involves such difficult trade-offs: wait longer and the disease causes more damage, but operate earlier and the brain may not have had as much time to shift functions to the healthy side.
When It Starts in Adulthood
Though Rasmussen encephalitis is overwhelmingly a childhood disease, adult-onset cases do occur, and they tend to behave differently. Compared with the childhood form, adults more frequently experience complex partial seizures rather than the relentless focal jerking of epilepsia partialis continua. The disease tends to progress more slowly, with a longer delay before motor deficits appear. Cognitive deterioration is generally less severe, and overall outcomes are somewhat better.22PubMed. Late-onset Rasmussen Encephalitis: A literature appraisal
The slower pace of adult-onset disease can be a double-edged sword diagnostically. Because the presentation is less dramatic and less classically “Rasmussen-like,” adult patients often wait longer before the correct diagnosis is considered. Adult brains also have less plasticity for functional reorganization after surgery, making the decision to proceed with hemispherotomy even more consequential and often even more difficult for clinicians and patients to accept. Many adult patients are managed with immunotherapy for longer before surgery enters the conversation, though the same general principle applies: drugs slow the decline but rarely stop it completely.
The Ongoing Search for Better Treatments
Rasmussen encephalitis sits in an uncomfortable gap in modern neurology. It is too rare to attract large clinical trials, yet too devastating to accept the current treatment options as adequate. The most aggressive immunotherapy regimens, including drugs like alemtuzumab that powerfully deplete T cells, have shown the strongest effects on reducing brain inflammation but come with serious side effects that limit their use.23PubMed Central. An immunotherapy effect analysis in Rasmussen encephalitis
Researchers are working to develop more precise biomarkers, including blood-based measures of neural injury like neurofilament light chain and inflammatory cytokine panels, that could help diagnose the disease earlier and track whether treatments are actually dampening the underlying inflammatory process in real time. Better biomarkers would also make it feasible to run smaller, smarter clinical trials in this rare-disease population. The genetic findings linking HLA variants and antiviral-response genes to the disease raise the possibility, still speculative, that future treatments could be tailored to an individual patient’s immune profile. For now, the practical reality is that most patients will face the same difficult sequence: try immunotherapy early and aggressively, and if the disease continues to advance, prepare for hemispherotomy, a surgery that saves children from a devastating disease at a steep but increasingly well-understood cost.